Is MiMedx Group Inc (MDXG) overvalued? · P/E 18, rev $123.4M
MiMedx Group Inc (MDXG) is a biotechnology company listed on US.
This page asks whether MiMedx Group Inc (MDXG) looks expensive on cached numbers — not a short thesis.
Latest reported MDXG revenue for 2026-06-30 was $123.4M. Net income was -$25.7M. MDXG currently screens at market cap $537.7M and trailing P/E 18.1.
MDXG currently screens at market cap $537.7M and trailing P/E 18.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MDXG 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MDXG stock page for the full model, not this heading.
Not investment advice.